Investor Presentation

72 Investor presentation First six months of 2022 The CagriSema phase 3 programme, REDEFINE, is expected to begin in the fourth quarter of 2022 N = 2500 REDEFINE 1 trial design CagriSema 2.4 mg/2.4 mg1 Cagrilintide 2.4 mg¹ Semaglutide 2.4 mg1 Placebo¹ N=800 REDEFINE 2 trial design CagriSema 2.4 mg/2.4 mg1 Placebo¹ + + Week 0 16 + 68 75 Dose escalation Treatment maintenance Follow- up Inclusion criteria REDEFINE 1: ⚫ BMI: ≥ 30 kg/m² or ≥ 27 kg/m² and ≥1 comorbidity Excludes diabetes diagnosis or HbA1c ≥ 6.5% REDEFINE 2: BMI: ≥ 27 kg/m² . Type 2 diabetes, HbA1c <10% Primary endpoints: Novo NordiskⓇ ㅏ Week 0 + 16 68 75 Dose escalation Treatment maintenance Follow- up Confirmatory secondary endpoints: • Change in body weight (%) Achieve ≥ 5% body weight reduction Change in waist circumference HbA1c Systolic blood pressure Patient reported outcomes² 1As an adjunct to a reduced-calorie diet and increased physical activity in adults with obesity or overweight. 2 Patient reported outcomes include (IWQOL-Lite-CT, SF-36v2, and Vitality score) CagriSema: Cagrilintide in combination with semaglutide; T2DM: Type 2 diabetes; BMI: Body mass index; HbA₁: Hemoglobin A₁ IWQOL-Lite-CT: Impact of weight on quality of life - lite, clinical trials version; Short form 36v2

View entire presentation